2-Adrenergic Receptor
Gene and Desensitization in Human Airway
Smooth Muscle
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
ABSTRACT |
|---|
|
|
|---|
We examined the influence of two common polymorphic forms of
the
2-adrenergic receptor (
2AR): the Gly16 and Glu27 alleles, on
acute and long-term
2AR desensitization in human airway smooth muscle (HASM) cells. In cells from 15 individuals, considered without respect to genotype, pretreatment with Isoproterenol (ISO) at 10
7 M for 1 h or 24 h caused approximately 25% and 64%
decreases in the ability of subsequent ISO (10
6 M) stimulation to
reduce HASM cell stiffness as measured by magnetic twisting cytometry. Similar results were obtained with ISO-induced cyclic
adenosine monophosphate (cAMP) as the outcome indicator. Data were then stratified post hoc by genotype. Cells containing at
least one Glu27 allele (equivalent to presence of the Gly16Glu27 haplotype) showed significantly greater acute desensitization than did cells with no Glu27 allele, whether ISO-induced cell stiffness (34% versus 19%, p < 0.03) or cAMP formation (58% versus 11%, p < 0.02) was measured. Likewise, cells with any Glu27 allele showed greater long-term desensitization of cell stiffness and cAMP formation responses than did cells without the Glu27 allele. The distribution of genotypes limited direct conclusions about the
influence of the Gly16 allele. However, presence of the Gly16Gln27 haplotype was associated with less acute and long-term desensitization of ISO-induced cAMP formation than was seen in cells without the Gly16Gln27 haplotype (14% versus 47%, p < 0.09 for
short-term desensitization; 32% versus 84%, p < 0.01 for long-term desensitization), suggesting that the influence of Glu27 is
not through its association with Gly16. The Glu27 allele was in
strong linkage disequilibrium with the Arg19 allele, a polymorphic
form of the
2AR upstream peptide of the 5'-leader cistron of the
2AR, and this polymorphism in the
2AR 5'-flanking region may
explain the effects of the Glu27 allele. Cells with any Arg19 allele
showed significantly greater acute and long-term desensitization
of ISO-induced cAMP formation than did cells without the Arg19
allele (54% versus 2%, p < 0.01 for short-term desensitization;
73% versus 35%, p < 0.05 for long-term desensitization). Similar
results were obtained for ISO-induced changes in cell stiffness.
Thus, the presence of the Glu27 allele is associated with increased
acute and long-term desensitization in HASM.
| |
INTRODUCTION |
|---|
|
|
|---|
-Agonists are the most widely used form of acute treatment
for symptomatic asthma. Within the airway, binding of these
agents to
2-adrenergic receptors (
2AR) in airway smooth
muscle (ASM) results in bronchodilation. There are at least
four missense single nucleotide polymorphisms in the coding
region of the
2AR (1). Two of them, an Arg
Gly mutation at
position 16 and a Gln
Glu mutation at position 27, have been
studied extensively because of their high prevalence in the
population and the possibility that they may contribute to the
pathogenesis of asthma (1). Although no polymorphism has
been found to occur more commonly in asthmatic than in normal subjects, the Gly16 and Glu27 polymorphisms have been
shown to influence the response to asthma treatment. The
mechanistic basis for these associations remains to be established. One possibility is that endogenous catecholamines or
inhaled
-agonists enhance downregulation when specific
polymorphisms of the
2AR are present. Green and colleagues
reported that when Chinese hamster fibroblasts (which do not
express
2AR) are transfected with this receptor and exposed
to the
-agonist isoproterenol (ISO) for 24 h,
2AR expression
decreases (11). In cells transfected with the Gly16 variant of
the receptor, ISO causes a greater decrease in
2AR number
than in cells transfected with the wild-type receptor. In contrast, the Glu27 mutation is protective against ISO-induced decreases in
2AR expression. Similar results were observed in cultured human airway smooth-muscle (HASM) cells (12).
The decrease in the
2AR number caused by such long-term
-agonist exposure has been shown in other cell types to
be the result of decreased transcription, decreased messenger
RNA (mRNA) stability, and degradation of the
2AR protein
(13). Acute desensitization, in contrast, results from phosphorylation of the receptor and subsequent uncoupling of the
receptor from Gs (17, 18). Because long-term and acute desensitization involve distinct mechanisms, the influence of polymorphisms of the
2AR on long-term desensitization does not
predict their influence on acute desensitization.
The purpose of this study was to characterize the effects of
the Gly16 and the Glu27
2AR alleles on acute desensitization of the receptor in HASM cells, and to compare these effects
with the effects of the two alleles on long-term desensitization.
To assess desensitization, we measured functional outcomes,
consisting of ISO-induced changes in cyclic adenosine monophosphate (cAMP) formation and ISO-induced changes in cell
stiffness as measured by magnetic twisting cytometry (MTC),
rather than measuring
2AR number. Surprisingly, results
with HASM cells derived from 15 different donors indicated
that cells from individuals who were either homozygous or
heterozygous for Glu27 showed both greater short- and long-term desensitization than occurred in cells from individuals
who were homozygous for Gln27, even though Green and colleagues had previously reported that Glu27 is protective
against desensitization (11, 12).
The Glu27 allele has been found to be in strong linkage disequilibrium with an unusual polymorphism in the 5' flanking
region of the
2AR gene (19). A short open reading frame in
the 5' leader cistron (5'LC) encodes a 19-amino-acid peptide,
termed the
2AR-upstream peptide (BUP), and this peptide
has been shown to inhibit
2AR translation (20). A single nucleotide mutation results in an Arg
Cys mutation at amino
acid 19 of the BUP, and the presence of Arg19 as compared
with Cys19 has been associated with decreased
2AR expression in transfected COS-7 and in cultured HASM cells (19). It
is possible that the influence of Glu27 on desensitization results from its linkage disequilibrium with the Arg19 allele.
| |
METHODS |
|---|
|
|
|---|
Cell Culture
Human tracheas were obtained from lung transplant donors in accordance with procedures approved by the University of Pennsylvania Committee on Studies Involving Human Beings. Tracheal smooth-muscle cells were harvested from the tracheas as previously described (21). The cells were then grown in plastic flasks in Ham's F12 medium with 10% fetal calf serum (FCS) that was supplemented with penicillin (100 U/ml), streptomycin (0.1 mg/ml), NaOH (12 mM), amphotericin-B (2.5 µg/ml), CaCl2 (1.6 mM), and L-glutamine (2 mM). Medium was replaced every 3 to 4 d, and cells were passaged with 0.25% trypsin and 1 mM ethylene diamine tetraacetic acid (EDTA) every 10 to 14 days. Cells were studied in Passages 4 to 7.
Experimental Protocol
In HASM cells from 15 different donors, we examined short-term and
long-term desensitization of the
2AR by measuring the effects of
pretreatment with ISO (10
7 M) for 1 h or 24 h on subsequent responses to ISO (10
6 M). We found this concentration of ISO (10
7 M)
to induce significant but not maximal desensitization, both acutely
and on a long-term basis, allowing us to make comparisons among
treatment groups. Cell stiffness measured by MTC (see the subsequent discussion), and cAMP formation, were used as outcome indicators. For each donor, cells were studied on from two to six experimental days. For each set of experiments, two flasks of confluent
HASM cells from the same passage were serum-deprived and supplemented with insulin at 5.7 µg/ml and transferrin at 5 µg/ml at 24 to 36 h
before use, since these conditions maximize expression of smooth-muscle-specific contractile proteins (21, 25). At the same 24- to 36-h
time point, both flasks were also treated with indomethacin (10
6 M).
We used indomethacin to suppress differences in endogenous prostaglandin release among donors, since this variation might influence
responses to ISO through heterologous desensitization (23). Approximately 3 h later, one flask was treated with ISO (10
7 M) and the
other flask was not treated (control). On the morning of the experimental day (20 h after ISO treatment), cells were passaged and plated
at: (1) 20,000 cells/well on collagen I (500 ng/cm2)-coated bacteriologic plastic dishes (96-well Removawells; Immulon 2; Dynatech Laboratories, Chantilly, VA) for use in the MTC experiments; or (2) at
100,000 cells/well in 24-well plates for cAMP measurements. Indomethacin and ISO were added to appropriate wells. In approximately half of the untreated wells, ISO (10
7 M) was added 1 h before
cell-stiffness measurements or before the cAMP assay, for the determination of short-term desensitization.
Cell-stiffness measurements with MTC were made from 2 to 10 h
after plating, on an alternating basis among wells of the three study
cell groups (untreated, treated with ISO for 24 h, treated with ISO for
1 h). On each experimental day, two or three wells of HASM cells
from a single individual were studied in each treatment group. ISO
was removed when magnetic beads were added 20 min before the
cell-stiffness measurements. For cell-stiffness measurements, responses to ISO and dibutyryl-cAMP (db-cAMP) were obtained as follows: first, from two to four measurements of cell stiffness were made
under baseline conditions. Beginning at 1 min after the addition of
ISO (10
6 M), from two to four measurements of cell stiffness were
again obtained. This concentration of ISO has been shown in other
experiments to generate maximal responses to ISO. db-cAMP, at a
concentration known to produce maximal effects (10
3 M), was added
to the same wells, and from two to four measurements of stiffness
were again made.
For cAMP measurements, from four to eight wells of HASM cells
were plated for each treatment group. Cells were allowed to readhere
for 4 h at 37° C, at which time the medium was replaced with 0.5 ml of
phosphate-buffered saline containing 0.1 mM 3-isobutyl-1-methylxanthine and 300 µM ascorbic acid. ISO was not readded, and 30 min
later, the cells either were treated with ISO (10
6 M) or were left untreated for measurement of basal cAMP formation. The cell supernatant containing cAMP was collected 10 min later, and cAMP was assayed with a Rainen [125I]cAMP radioimmunoassay kit (New England
Nuclear, Boston, MA) as previously described (22).
MTC
MTC was used to measure cytoskeletal mechanics of HASM cells, as previously described (22, 23, 28, 29). In this technique, ferromagnetic beads of 4.5-µm diameter and coated with a synthetic Arg-Gly-Asp (RGD)-containing peptide are added to wells containing HASM cells. The beads bind to cells through integrin receptors on the cell surface that recognize the RGD sequence. The wells containing the cells are placed within the magnetometer, where the beads are then magnetized with a brief 1,000-G pulse so that their magnetic moments are aligned in one direction, parallel to the surface on which the cells are plated. Subsequent application of a much smaller external magnetic field, orthogonal to the first field, produces a magnetic torque (or twisting force), in this case 80 dynes/cm2, causing the beads bearing the cells to rotate as would a compass needle. Bead rotation is opposed, however, by reaction forces that develop within the cytoskeleton to which the beads are bound through the integrin receptors. MTC measures the resulting angular rotation (strain) of the magnetic bead in relation to the applied twisting stress, and the ratio of applied stress to strain is defined as the cell stiffness. Thus, the cell-stiffness measurements made by MTC reflect the resistance to shape distortion of the cytoskeleton, including that produced by actin and myosin. Consequently, stiffness increases with the application of contractile agonists and decreases after the addition of dilating agonists (28). However, although stiffness measurements made by MTC most likely reflect the effects of contractile and dilator agonists on actomyosin interactions, stiffness is likely to be a surrogate marker rather than a direct measure of the contraction and shortening of smooth muscle.
2AR Genotyping
DNA was isolated from HASM cells from each of the 15 donors through standard methods.
The region containing the
2AR polymorphism at position 27 was
amplified with the forward primer 5'-AACGGCAGCGCCTTCTTGCTG-3' and the reverse primer 5'-AAAGGGCACCACTGCCAG-3'. Each PCR reaction contained 100 ng of DNA, PCR buffer
with 1.5 mM MgCl2 (Promega, Madison, WI), 200 µM deoxynucleotide triphosphates, and 10 pmol of each primer in a total volume of
25 µl of reaction mixture. Conditions for polymerase chain reaction
(PCR) were 94° C for 6 min, followed by 35 cycles of 30 s at 94° C, 30 s
at 62° C, and 30 s at 72° C, with a final extension time of 5 min at 72° C.
Restriction fragment length polymorphism (RFLP) was produced in 15 µl of PCR reaction mixture digested with 2 U of Bbv I and Buffer 2 (New England Biolabs, Boston, MA), according to the manufacturer's recommendations for 2 h at 37° C. The digest products were resolved by electrophoresis on a 2% agarose gel and stained with ethidium bromide. Bbv I digests only the Gln27 allele, to produce 180-bp and 51-bp fragments, whereas the uncut Glu27 allele gives a 231-bp fragment.
Genotyping at the
2AR polymorphism at position 16 was done
according to the method described by Martinez and coworkers (6). The
2AR-16-containing region was amplified with the primers 5'- GCCTTCTTGCTGGCACCCCAT-3' and 5'-CAGACGCTCGAACTTGGCCATG-3'. The underlined bases were modified from the reported sequence to create an Nco I site. The reverse primer contains
an Nco I site and yields products from both alleles. The PCR product
of the Gly16 allele contains the Nco I site in the 5'-primer. The PCR
reaction conditions used for the
2AR-16 genotyping study were similar to the conditions described for the
2AR-27 study.
RFLP was produced in 10 µl of the PCR product digested with 2 U of NcoI and Buffer 4 (New England Biolabs) for 2 h at 37° C. The digest products were resolved by electrophoresis on a 4% NuSieve (BioWhittaker Molecular Applications, Rockland, ME) agarose gel and stained with ethidium bromide. The uncut PCR product was 167 bp in length. NcoI digests the PCR product to produce a 145-bp fragment from the Arg16 allele and a 127-bp fragment from the Gly16 allele.
The accuracy of both genotyping methods was established by direct sequencing of PCR products amplified over the region of the receptor containing both polymorphic sites.
Haplotype assignments for the combination of amino acids 16 and
27 were made if homozygosity was present at either allele. For individuals heterozygous at both alleles, the region of the receptor containing both polymorphic sites was amplified by using the primers
5'-AACGGCAGCGCCTTCTTGCTG-3' and 5'-CAGACGCTCGAACTTGGCCATG-3', with PCR conditions identical to those used
for amplification of the
2AR-27 polymorphism. This PCR product
was cloned with the TOPO TA Cloning Kit (Invitrogen, Carlsbad,
CA) according to the manufacturer's instructions, and direct sequencing was performed for haplotype determination.
Genotyping at the 5'LC polymorphism was done with a modification of the method described by McGraw and associates (19). This region was amplified with the primers 5'-GCTGAATGAGGCTTCCAGGC-3' and 5'-CGCATGGCTTCTATTGGGTG-3'. Conditions for PCR were 94° C for 3 min, followed by 40 cycles of 45 s at 94° C, 45 s at 59° C, and 1 min at 72° C, with a final extension time of 7 min at 72° C.
RFLP was produced in 15 µl of PCR reaction mixture digested with 2 U of MspA1I and Buffer 2 according to the manufacturer's recommendations, for 16 h at 37° C. The digest products were resolved by electrophoresis on a 4% NuSieve agarose gel and stained with ethidium bromide. MspA1I digests only the Arg19 allele of the BUP to produce 103-bp and 60-bp fragments, whereas the uncut Cys19 allele was 167 bp in length.
Data Analysis and Statistics
Analysis of variance was used to determine statistical significance among the three treatment groups before the data were stratified by genotype. Linear mixed-effects models were used to assess whether, and the degree to which, genotype had a modifying effect on the mean shift in the outcome variable from baseline. The fixed-effects component of each model allowed the mean shift to be different for each group. The random-effects component mimicked the fixed-effects component according to the individual donor. The variance components for random effects were estimated by using restricted maximum likelihood via the function lme in the S-PLUS (MathWorks, Seattle, WA, 1996) software package. Values of p correspond to the significance of the mean modifying effect parameter obtained from that package. Data are presented as mean ± SE.
Reagents
Tissue culture reagents and drugs used in the study were obtained
from Sigma (St. Louis, MO), with the exception of amphotericin-B and trypsin-EDTA solution, which were purchased from GIBCO
(Grand Island, NY). Indomethacin was dissolved at 10
2 M in dimethylsulfoxide on each experimental day, and was then further diluted in
medium before treating cells with it. ISO was dissolved at 10
1 M in
distilled water on each experimental day, and because ISO is rapidly
oxidized, dilutions of ISO in medium were made immediately before
treating cells with ISO. db-cAMP was dissolved at 10
1 M in distilled
water and frozen in aliquots until the day of use.
| |
RESULTS |
|---|
|
|
|---|
ISO Effects Not Stratified by Genotype
In untreated (control) HASM cells from 15 different donors,
ISO (10
6 M) produced a response that was 76 ± 2% (mean ± SE) of the maximal decrease in cell stiffness (Figure 1). Maximal response was defined as the decrease in cell stiffness in
response to db-cAMP (10
3 M), as has been previously described (22, 28), and did not differ among treatment groups.
In cells pretreated with ISO (10
7 M) for 1 h and then washed
for 20 min, subsequent ISO stimulation produced a significantly smaller response (57 ± 3% of maximal, p < 0.0001). In
cells pretreated with ISO (10
7 M) for 24 h, the ISO response
was even smaller (27 ± 3% of maximal, p < 0.0001). We then
calculated the extent of desensitization from these values. For
cells from all 15 donors, the degree of short-term (1 h) desensitization (25%) was less than half the degree of long-term (24 h)
desensitization (64%).
|
Exposure to ISO for 1 h and for 24 h had effects on ISO-induced cAMP formation similar to those on cell stiffness. In
untreated (control) cells, ISO (10
6 M) increased cAMP formation by 62.5 ± 5.8 pmol/106 cells above baseline values
(22.1 ± 1.8 pmol/106 cells) (Figure 2), which was consistent
with the approximately fourfold increase seen in untreated
cells in previous experiments (22). Prior treatment with
ISO (10
7 M) for 1 h resulted in significantly less of an increase in cAMP formation (42.6 ± 8.0 pmol/106 cells, p < 0.001), whereas prior treatment with ISO for 24 h resulted in
even less of an increase in cAMP formation (22.7 ± 4.0 pmol/
106 cells, p < 0.0001). Since cAMP formation at baseline did
not differ among the treatment groups, desensitization was
calculated from the ISO-induced increase in cAMP formation
from baseline. The degree of acute (32%) and long-term
(64%) desensitization in terms of ISO-induced cAMP formation was nearly identical to the degree of desensitization measured with cell-stiffness responses.
|
Data Stratified by Genotype
Table 1 shows the distribution of genotypes at amino acid positions 16 and 27 of the
2AR for the HASM cells from the 15 donors in the study, and Table 2 shows the distribution of the haplotype combination for these genotypes. The distribution
that we found was similar to what has been reported in the literature (1).
|
|
We stratified cell stiffness and cAMP responses to ISO by genotype and haplotype. Because there was no effect of genotype or haplotype on responses to ISO in untreated cells, values of ISO-induced cell-stiffness responses after 1 h or 24 h of ISO exposure were normalized, for each donor, as a percent of ISO-induced stiffness responses in untreated cells.
The presence of the Glu27 allele was associated with significantly greater acute desensitization (34 ± 6%) of ISO-induced changes in cell stiffness than was the absence of the Glu27 allele (19 ± 5%) (Figure 3, p < 0.03). Since the Arg16Glu27 haplotype is rare (present in less than 1% of the population [6, 7, 9, 10, 30]) and was not present in our sample, presence (or absence) of the Glu27 allele in our data is equivalent to presence (or absence) of the Glu16Gln27 haplotype. Cells from donors with the Glu27 allele also showed significantly greater long-term desensitization (76 ± 6%) than did cells from donors without Glu27 (59 ± 5%) (Figure 3, p < 0.02). Similar results were obtained when we examined changes in ISO-induced cAMP formation (Figure 4). Cells from donors without the Glu27 allele exhibited virtually no acute desensitization (10 ± 12%), whereas the presence of Glu27 was associated with 58 ± 14% desensitization (Figure 4, p < 0.02). Although the difference was not statistically significant (p = 0.18), cells from individuals with the Glu27 allele also tended to exhibit greater long-term desensitization (70 ± 17%) than did cells from individuals without Glu27 (44 ± 13%) (Figure 4). The distribution of genotypes (only one donor was homozygous for Glu27) prevented a comparison between cells from donors homozygous for Glu27 and cells from donors heterozygous or homozygous for Gln27.
|
|
We also examined the importance of the Gly16 polymorphism. The presence of Gly16 appeared to be associated with greater acute desensitization when cell stiffness was the outcome indicator, although the results were not statistically significant (Figure 5, p < 0.07). The presence of Gly16 did not appear to influence long-term desensitization of ISO-induced cell stiffness (Figure 5) or of ISO-induced cAMP formation (data not shown). The distribution of genotypes may have limited our ability to detect an effect of the Gly16 allele, since only two of the 15 HASM cell donors were homozygous for the Arg16 allele.
|
Since the presence of Glu27 was always associated with the presence of Gly16 in our population sample, we wanted to determine whether the effects of Glu27 resulted from its being in linkage disequilibrium with Gly16. To answer this question, given the distribution of haplotypes among our donors, we stratified our data, comparing results in the presence and absence of the Gly16Gln27 haplotype. Presence of the Gly16Gln27 haplotype was associated with significantly less long-term desensitization of ISO-induced cAMP formation (32 ± 14%) than was absence of the Gly16Gln27 haplotype (82 ± 12%, p < 0.01) (Figure 6). Cells from donors with the Gly16Gln27 haplotype also tended to exhibit less acute desensitization (47 ± 13%) than did cells from donors without the Gly16Gln27 haplotype (82 ± 12%, p < 0.09). Taken together, these results suggest that the influence of Glu27 did not occur through its association with Gly16.
|
We also wanted to determine whether the effects of the
Glu27 allele resulted from its being in linkage disequilibrium
with the Arg19 allele of the BUP in the 5' LC of the
2AR,
since the Arg19 polymorphism has been associated with decreased
2AR expression in transfected COS-7 and in cultured
HASM cells (19). The Arg19 polymorphism of the BUP has
previously been shown to be in strong linkage disequilibrium
with Glu27, whereas the Cys19 polymorphism has been shown
to be in strong linkage disequilibrium with Arg16 (19). Our results (Table 3) were consistent with these previous observations. We then stratified our data according to the presence or
absence of the Arg19 allele. Presence of the Arg19 allele was associated with significantly greater acute desensitization (54 ± 12%) of ISO-induced cAMP formation than was its absence (2 ± 14%) (Figure 7, p < 0.01). Cells from donors with the Arg19
allele also showed significantly greater long-term desensitization (73 ± 12%) than did cells from donors without the Arg19
allele (35 ± 16%, p < 0.01; Figure 7). Similar results were obtained for ISO-induced changes in cell stiffness (data not
shown). Presence of the Arg19 allele was associated with
greater acute (p < 0.01) and long-term (p < 0.06) desensitization.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
Prior treatment of HASM cells with the
-agonist ISO for 1 h
or 24 h decreased the cells' response to subsequent ISO stimulation, as assessed either with cell stiffness (Figure 1) or cAMP
formation (Figure 2). The genotypes of the
2AR expressed in
the HASM cells from the 15 study donors were then determined post hoc. The presence of Glu27 (equivalent to the
Gly16Glu27 haplotype) was associated with significantly greater
acute desensitization, whether ISO-induced cell-stiffness responses (Figure 3) or ISO-induced cAMP formation (Figure
4) was used as the outcome indicator. Presence of the Glu27
allele was also associated with significantly greater long-term desensitization of ISO-induced cell-stiffness responses (Figure 3), and a similar trend was observed for ISO-induced cAMP
responses (Figure 4). The distribution of genotypes, with only
two donors homozygous for the Arg16 allele (Table 1), limited
direct conclusions about the influence of the Gly16 allele (Figure 5). However, presence of the Gly16Gln27 haplotype was
associated with significantly less acute and long-term desensitization, whether ISO-induced changes in cAMP formation
(Figure 6) or cell stiffness (data not shown) were measured.
We also confirmed that the Arg19 allele of the BUP in the
5'LC of the
2AR is in strong linkage disequilibrium with the
Glu27 allele (Table 3), and we showed that it is also significantly associated with increased desensitization to ISO-induced changes in cAMP formation (Figure 7) and cell stiffness (data not shown).
In our sample, presence of the Glu27 allele was always associated with presence of the Gly16 allele, with the result that the effects of the Glu27 allele could have come from its being in linkage disequilibrium with Gly16. Ideally, an assessment of the role of the Glu27 allele could be achieved with a haplotype comparison of cells from donors homozygous for the Gly16Glu27 haplotype with cells from donors homozygous for the Gly16Gln27 haplotype. Given our limited sample size and the distribution of haplotypes in our donors, such a comparison was not possible, since even with 15 donors we did not find a single one who was homozygous for the Gly16Glu27 haplotype. However, when we performed a haplotype analysis in which we assessed the influence of the presence or absence the Gly16Glu27 haplotype, we saw increased desensitization in the presence of even a single Gly16Glu27 allele (Figures 3 and 4). In contrast, the presence of even a single Gly16Gln27 haplotype was associated with decreased desensitization (Figure 6). These data suggest that the influence of Glu27 does not occur through its association with Gly16.
Current understanding of how polymorphic forms of the
2AR influence desensitization is based on data from only two
studies, in which only long-term exposure was studied and
2AR expression was the outcome indicator (11, 12). Our
results extend the observations in those studies in several
significant ways. First, we measured both acute and long-term
desensitization. Acute desensitization is known to occur within
minutes of continuous agonist exposure, as the result of phosphorylation and decoupling of the
2AR from Gs (18), whereas
desensitization over the longer term is associated with a decrease in receptor number as a result of decreased mRNA expression and increased receptor degradation (14). On the
basis of the distinct mechanisms involved in acute and long-term desensitization, we reasoned that the role of
2AR polymorphisms in short-term and long-term desensitization might
not necessarily be the same. Corroborating this, our results indicated that the Glu27 allele was associated with increased
short-term desensitization. To our surprise, we also observed
that Glu27 was associated with increased long-term desensitization, even though Green and colleagues had previously reported that Glu27 is protective against desensitization (11, 12).
We are confident of the validity of our results in that we used
two independent functional indicators to assess desensitization (cell stiffness and cAMP formation), and found the same
trend with both methods. Further, we measured responses in
HASM cells from 15 individuals.
Two explanations are possible for the dichotomy between
our results and those of Green and colleagues (11, 12). First, with respect to Glu27, the genotypes of our cells and those of Green and colleagues (12) were not the same. Their conclusion, that homozygosity for Glu27 is protective against desensitization, was based on observations in HASM cells from a
single individual whose
2AR contained the Glu27 allele in
linkage with the Arg16 allele, giving the rare Arg16Glu27 haplotype, which is present in only about 1% of the population (6,
7, 9, 10, 30). In Green and colleagues' previous study, with
transfected Chinese hamster fibroblasts, homozygosity for the
Arg16Glu27 haplotype was protective against desensitization
of
2AR density, but cells homozygous for the Gly16Glu27
haplotype showed desensitization similar to that seen in wild-type cells (homozygous for Arg16Gln27) (11). The Arg16Glu27
haplotype was not present in our 15 donors.
The other potential reason for our findings is that receptor
density may not be the most relevant marker for assessing
2AR desensitization. Previous studies have shown that the
physiologic responsiveness of the
AR system is not associated with a parallel change in
AR density. Nishikawa and coworkers exposed guinea pig lung to a
-agonist for 7 d and
measured a 46% decrease in
2 receptor density in ASM and a
75% decrease in
2AR mRNA expression in ASM, but only a
10% decrease in maximum relaxation response to a
-agonist
(14). Other studies have confirmed these findings, suggesting
the presence of a substantial spare
AR population (31, 32).
Although Green and colleagues emphasized increased desensitization of ISO-induced
2AR expression, their results are
consistent with ours in that they also saw no effect of Gly16 on
long-term desensitization when ISO-induced cAMP accumulation, rather than
2AR expression, was the outcome indicator (12).
We do not know the mechanism by which the presence of
Glu27 increases the degree of acute and long-term desensitization in HASM cells. One possibility is that the coding block
polymorphism has no primary effect but is in linkage disequilibrium with a polymorphism in the 5'-flanking region of the
2AR that is important for desensitization. The Glu27 polymorphism has been shown to be in strong linkage disequilibrium with a Cys
Arg polymorphism in the BUP of the 5'LC
of the human
2AR gene (19). This Arg19 5'LC polymorphism has been shown to result in decreased
2AR expression both in transfected COS-7 cells and in HASM cells. Therefore, the influence of Glu27 may be the result of decreased
2AR
expression at baseline, resulting in a cell that is more easily desensitized. In this study, we also demonstrated strong linkage
disequilibrium between presence of the Arg19 polymorphism
and presence of the Glu27 polymorphism (Table 3). As indicated, one donor homozygous for the Gln27 allele was heterozygous for Arg19Cys19, which accounts for the differences
in desensitization reflected by cAMP formation seen in Figures 4 and 7. If anything, presence of the Arg19 polymorphism of the BUP of the 5'LC region was associated with at least as much long-term and acute desensitization (Figure 7) as was
seen in the presence of the Glu27 allele (Figure 4), suggesting
that the effects of Glu27 may result from its being in linkage
disequilibrium with the Arg19 allele.
However, the influence of Glu27 on desensitization might
also be the result of direct effects on the receptor, rather than of effects on its level of expression. In their study in transfected Chinese hamster fibroblasts, Green and colleagues detected no difference in the sequestration of receptors or in the
distribution of cell surface versus internalized
2AR receptors
in the basal state among the four combinations of
2AR polymorphisms at amino acids 16 and 27 (11). However, they demonstrated that
2AR homozygous for the Glu27 allele had altered electrophoretic mobility as compared with wild-type
2AR, suggesting that
2AR with the Glu27 allele do not reach
the mature wild-type conformation. Mutated
2AR lacking amino acids 21 to 30 have been shown to be poorly processed
by the cell to a mature protein (33). Thus, the addition of a
negatively charged amino acid (Glu27) in the region from
amino acids 21 to 30 may alter the ability of the receptor to
reach the cell surface, leading to increased degradation of receptors after their initial synthesis or after internalization. In
addition, McGraw and associates reported that long-term desensitization was attenuated with
2AR lacking phosphorylation sites for
-adrenergic receptor kinase (
ARK), one of the
G-protein-related kinases known to be important in acute
desensitization (34). Perhaps the presence of a negatively charged Glu27 induces a conformational change in the receptor, increasing either the ability of
ARK to phosphorylate
the receptor or of the receptor to remain phosphorylated, resulting in increased desensitization.
To our knowledge, only one clinical study has been reported in which
-agonist desensitization in human subjects
was measured in vivo. That study demonstrated greater bronchodilator desensitization in the presence of Glu27 when
forced expiratory flow from 25% to 75% of FVC was used as
the clinical outcome indicator, which is in accord with our data
(4). However, the in vivo study also found that Gly16 was associated with greater desensitization when FEV1 was used as
the outcome indicator. Since six of the 10 individuals in the in
vivo study who were homozygous for Gly16 were also homozygous for Glu27, Glu27 was a prominent aspect of the
Gly16 effect. Other clinical studies have sought an association between genetic polymorphisms of
2AR and a variety of features that relate to asthma, including its prevalence, markers
of asthma severity, and persistent bronchial hyperreactivity
(1, 5), but the way in which asthma and airway reactivity
are linked to
2AR downregulation is not known.
The distribution of
2AR genotypes and haplotypes in our
study is fairly representative of that determined in larger population studies (1, 2, 4, 6, 30). Although only two donors were homozygous for Arg16, and this distribution limited direct comparisons with respect to the role of the Gly16 allele,
the prevalence of Arg16 in the general population is virtually
the same as in our population, at 13%. Another limitation was
that our sample included no donors homozygous for the
Gly16Gln27 haplotype. Not only would this haplotype be helpful in evaluating the role of the Gly16 allele, but also, two recent studies have suggested that presence of this haplotype is
more prevalent in persons with moderate asthma (9) and is associated with measured bronchial hyperresponsiveness (10).
One caveat of our in vitro study is that ASM cells, after a
few passages, may convert to a more synthetic phenotype,
with the result that the influence of genotype on desensitization may not necessarily be the same in cultured HASM cells
as it is in situ. We have previously demonstrated that nearly all
cultured HASM cells (98 ± 2%) express smooth-muscle-specific
-actin, as determined immunochemically, and that both
confluence and serum-free conditions increase actin expression (21). Although we do not know the extent to which
2AR
expression is altered in culture, the cAMP responses observed
in cultured HASM cells are quantitatively similar to those observed in ASM preparations obtained ex vivo (25).
In conclusion, we have provided in vitro evidence that presence of the Glu27 allele of the
2AR is associated with increased acute and long-term desensitization in HASM cells.
This effect may result from linkage disequilibrium with a polymorphism in the 5'LC region of the
2AR gene. Thus, the heterogeneity exhibited in response to asthma therapy may be influenced by specific genotypes of the
2AR.
| |
Footnotes |
|---|
Correspondence and requests for reprints should be addressed to Stephanie A. Shore, Ph.D., 655 Huntington Ave., Bldg. I, Rm. 311, Harvard School of Public Health, Boston, MA 02115.
(Received in original form September 10, 1999 and in revised form May 17, 2000).
Dr. Laporte is the recipient of an American Lung Association fellowship.Acknowledgments: The authors appreciate the help of Drs. Ben Fabry and Geoffrey Maksym in maintaining the magnetometer used in the magnetic twisting cytometry experiments.
Supported by grants HL-56383, HL-33009, HL55301, and AI40203 from the National Institutes of Health.
| |
References |
|---|
|
|
|---|
1.
Reihaus E,
Innis M,
MacIntyre N,
Liggett SB.
Mutations in the gene encoding for the
2-adrenergic receptor in normal and asthmatic subjects.
Am J Respir Cell Mol Biol
1993;
8:
334-339
.
2.
Turki J,
Pak J,
Green SA,
Martin RJ,
Liggett SB.
Genetic polymorphisms of the
2-adrenergic receptor in nocturnal and nonnocturnal
asthma.
J Clin Invest
1995;
95:
1635-1641
.
3.
Hall IP,
Wheatley A,
Wilding P,
Liggett SB.
Association of glu 27
2-adrenoceptor polymorphism with lower airway reactivity in asthmatic
subjects.
Lancet
1995;
345:
1213-14
[Medline].
4.
Tan S,
Hall IP,
Dewar J,
Dow E,
Lipworth B.
Association between
2-adrenoceptor polymorphism and susceptability to bronchodilator desensitization in moderately severe stable asthmatics.
Lancet
1997;
350:
995-999
[Medline].
5.
Liggett SB.
Polymorphisms of the
2-adrenergic receptor and asthma.
Am J Respir Crit Care Med
1997;
156:
S156-S162
6.
Martinez FD,
Graves PE,
Baldini M,
Solomon S,
Erickson R.
Association between genetic polymorphisms of the
2-adrenoceptor and response to albuterol in children with and without a history of wheezing.
J Clin Invest
1997;
100:
3184-3188
[Medline].
7.
Hancox RJ,
Sears MR,
Taylor DR.
Polymorphism of the
2-adrenoceptor and the response to long-term
2-agonist therapy in asthma.
Eur
Respir J
1998;
11:
589-593
[Abstract].
8.
Dewar JC,
Wheatley AP,
Venn A,
Morrison JFJ,
Britton J,
Hall IP.
2-adrenoceptor polymorphisms are in linkage disequilibrium but are not
associated with asthma in an adult population.
Clin Exp Allergy
1998;
28:
442-448
[Medline].
9.
Weir TD,
Mallek N,
Sandford AJ,
Bai TR,
Awadh N,
Fitzgerald JM,
Cockcroft D,
James A,
Liggett SB,
Pare PD.
2-adrenergic receptor
haplotypes in mild, moderate, and fatal/near fatal asthma.
Am J
Respir Crit Care Med
1998;
158:
787-791
10.
D'Amato M,
Vitiani LR,
Petrelli G,
Ferrigno L,
Pietro AD,
Trezza R,
Matricardi PM.
Association of persistent bronchial hyperresponsiveness with
2-adrenoceptor (ADRB2) haplotypes.
Am J Respir Crit
Care Med
1998;
158:
1968-1973
11.
Green SA,
Turki J,
Innis M,
Liggett SB.
Amino-terminal polymorphisms
of the human
2-adrenergic receptor impart distinct agonist-promoted
regulatory properties.
Biochemistry
1994;
33:
9414-9419
[Medline].
12.
Green SA,
Turki J,
Bejarno P,
Hall IP,
Liggett SB.
Influence of
2-
adrenergic receptor genotypes on signal transduction in human airway
smooth muscle cells.
Am J Respir Cell Mol Biol
1995;
13:
25-33
[Abstract].
13.
Hadcock JR,
Malbon CC.
Down-regulation of
-adrenergic receptors:
agonist-induced reduction in receptor mRNA levels.
Proc Natl Acad
Sci USA
1988;
85:
5021-5025
14.
Nishikawa M,
Mak JCW,
Shirasaki H,
Harding SE,
Barnes PJ.
Long-term exposure to norepinephrine results in down-regulation and reduced mRNA expression of pulmonary
-adrenergic receptors in
guinea pigs.
Am J Respir Cell Mol Biol
1994;
10:
91-99
[Abstract].
15. Collins S, Caron MG, Lefkowitz RJ. From ligand binding to gene expression: new insights into the regulation of G-protein-coupled receptors. Trends Biochem Sci 1992; 17: 37-39 [Medline].
16. Liggett SB, Lefkowitz RJ. Adrenergic receptor-coupled adenylyl cyclase systems: regulation of receptor function by phosphorylation, sequestration, and downregulation. In: Sibley DR, Housay MD, editors. Regulation of cellular signal transduction pathways by desensitization and amplification. New York: John Wiley & Sons; 1994. p. 71-97.
17.
Hall IP,
Daykin K,
Widdop S.
2-adrenoceptor desensitization in cultured human airway smooth muscle.
Clin Sci
1993;
84:
151-157
[Medline].
18.
Penn RB,
Reynold J,
Panetteiri A,
Benovic JL.
Mechanisms of acute desensitization of the
2-AR-adenylyl cyclase pathway in human airway
smooth muscle.
Am J Respir Cell Mol Biol
1998;
19:
338-348
19.
McGraw DW,
Forbes SL,
Kramer LA,
Liggett SB.
Polymorphisms of
the 5' leader cistron of the human
2-adrenergic receptor regulate
gene expression.
J Clin Invest
1998;
102:
1927-1932
[Medline].
20.
Parola AL,
Kobilka BK.
The peptide product of a 5' leader cistron in the
2 adrenergic receptor mRNA inhibits receptor synthesis.
J Biol Chem
1994;
269:
4497-4505
21.
Panettieri RA,
Murray RK,
DePalo LR,
Yadvish PA,
Kotlikoff MI.
A
human airway smooth muscle cell line that retains physiological responsiveness.
Am J Physiol
1989;
256:
C329-C335
22.
Shore SA,
Laporte J,
Hall IP,
Hardy E,
Panettieri JRA.
Effect of IL-1
on responses of cultured human airway smooth muscle cells to bronchodilator agonists.
Am J Respir Cell Mol Biol
1997;
16:
702-712
[Abstract].
23.
Laporte JD,
Moore PE,
Panettieri JRA,
Moller W,
Heyder J,
Shore SA.
Prostanoids mediate IL-1
induced
-adrenergic hyporesponsiveness in
human airway smooth muscle cells.
Am J Physiol
1998;
275:
L491-L501
24.
Moore PE,
Laporte JD,
Gonzalez S,
Moller W,
Heyder J,
Reynold J,
Panettieri A,
Shore SA.
Glucocorticoids ablate IL-1
induced
-adrenergic hyporesponsiveness in human airway smooth muscle cells.
Am J Physiol
1999;
277:
L932-L942
25.
Hall IP,
Kotlikoff M.
Use of cultured human airway myocytes for study
of airway smooth muscle.
Am J Physiol
1995;
268:
L1-L11
26.
Owens GK,
Loeb A,
Gordon D,
Thompson MM.
Expression of smooth
muscle specific
-isoactin in cultured human airway smooth muscle
cells: relationship between growth and cytodifferentiation.
J Cell Biol
1986;
102:
343-352
27. Panettieri RA, Yadvish PA, Kelly AM, Rubenstein NA, Kotlikoff MI. Histamine stimulates proliferation of human airway smooth muscle and induces c-fos expression. Am J Physiol 1990; 259: C329-C335 .
28.
Hubmayr R,
Shore SA,
Fredberg J,
Planus E,
Pannetieri JR,
Moller W,
Heyder J,
Wang N.
Pharmacologic activation changes stiffness of cultured human airway smooth muscle cells.
Am J Physiol
1996;
271:
C1660-C1668
29.
Wang N,
Butler JP,
Ingber DE.
Mechanotransduction across the cell surface and through the cytoskeleton.
Science
1993;
260:
1124-1127
30.
Large V,
Hellstrom L,
Reynisdottir S,
Lonnqvist F,
Eriksson P,
Lannfelt L,
Arner P.
Human
2 adrenoceptor gene polymorphisms are highly
frequent in obesity and associate with altered adipocyte
2 adrenoceptor function.
J Clin Invest
1997;
100:
3005-3013
[Medline].
31.
Nerme V,
Abrahamson T,
Vauquelin G.
Chronic isoproterenol administration causes altered
-adrenoceptor-Gs-coupling in guinea pig lung.
J Pharmacol Exp Ther
1990;
252:
1341-1346
32.
Wong SK,
Buckner CK.
Studies on
-adrenoceptors mediating changes
in mechanical events and adenosine 3',5'-monophosphate levels:
guinea-pig trachea.
Eur J Pharmacol
1978;
47:
273-280
[Medline].
33.
Dixon RAF,
Irving SS,
Candelor MR,
Register RB,
Scattergood W,
Rands E,
Strader CD.
Structural features required for ligand binding
to the
-adrenergic receptor.
EMBO J
1987;
6:
3269-3275
[Medline].
34.
McGraw DE,
Donnelly ET,
Eason MG,
Green SA,
Liggett SB.
Role of
ARK in long-term agonist-promoted desensitisation of the
2-adrenergic receptor.
Cell Signal
1998;
10:
197-204
[Medline].
This article has been cited by other articles:
![]() |
C. Wang, M. T. Salam, T. Islam, M. Wenten, W. J. Gauderman, and F. D. Gilliland Effects of In Utero and Childhood Tobacco Smoke Exposure and {beta}2-Adrenergic Receptor Genotype on Childhood Asthma and Wheezing Pediatrics, July 1, 2008; 122(1): e107 - e114. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yao, M. J. Delmonico, S. M. Roth, B. D. Hand, J. Johns, J. Conway, L. Douglass, and B. F. Hurley Adrenergic Receptor Genotype Influence on Midthigh Intermuscular Fat Response to Strength Training in Middle-Aged and Older Adults J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2007; 62(6): 658 - 663. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Hawkins, K. Tantisira, D. A. Meyers, E. J. Ampleford, W. C. Moore, B. Klanderman, S. B. Liggett, S. P. Peters, S. T. Weiss, and E. R. Bleecker Sequence, Haplotype, and Association Analysis of ADRbeta2 in a Multiethnic Asthma Case-Control Study Am. J. Respir. Crit. Care Med., November 15, 2006; 174(10): 1101 - 1109. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Moore, G. Cunningham, M. M. Calder, A. D. DeMatteo Jr., M. E. Peeples, M. L. Summar, and R. S. Peebles Jr. Respiratory Syncytial Virus Infection Reduces beta2-Adrenergic Responses in Human Airway Smooth Muscle Am. J. Respir. Cell Mol. Biol., November 1, 2006; 35(5): 559 - 564. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Snyder, K. C. Beck, N. M. Dietz, M. J. Joyner, S. T. Turner, and B. D. Johnson Influence of {beta}2-Adrenergic Receptor Genotype on Airway Function During Exercise in Healthy Adults Chest, March 1, 2006; 129(3): 762 - 770. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Taylor, M. J. Epton, M. A. Kennedy, A. D. Smith, S. Iles, A. L. Miller, M. D. Littlejohn, J. O. Cowan, T. Hewitt, M. P. Swanney, et al. Bronchodilator Response in Relation to {beta}2-Adrenoceptor Haplotype in Patients with Asthma Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 700 - 703. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Oostendorp, D. S. Postma, H. Volders, H. Jongepier, H. F. Kauffman, H. M. Boezen, D. A. Meyers, E. R. Bleecker, S. A. Nelemans, J. Zaagsma, et al. Differential Desensitization of Homozygous Haplotypes of the {beta}2-Adrenergic Receptor in Lymphocytes Am. J. Respir. Crit. Care Med., August 1, 2005; 172(3): 322 - 328. [Abstract] [Full Text] [PDF] |
||||
![]() |
|